Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
← catalyst calendarNCT05733598 · readout in 468 d
Sponsored by Replimune, Inc. (industry) · REPL — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
60estimated
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-01 | actual | When the study began enrolling |
| Primary completion | 2027-12-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hepatocellular Carcinoma
- Biliary Tract Cancer
Interventions
- Biological: RP2
- Biological: Bevacizumab — also filed as Avastin
- Biological: Atezolizumab — also filed as Tecentriq
- Biological: Durvalumab — also filed as Imfinzi
- Biological: RP2 Monotherapy — also filed as RP2
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate per modified RECIST 1.1
measured From Day 1 up to 3 years after first RP2 dose of last patient.
Permalink · REPL's whole pipeline · Catalyst calendar · Every registered study · What changed